Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 17/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13513491 | 0.90 | LTB4R2 (0.58) | LTB4R2AGTR1 | |
| SCHEMBL2853426 | 0.88 | LTB4R2 (0.61) | LTB4R2PTPN11PTPROAGTR1 | |
| SCHEMBL2860171 | 0.87 | NR1H4 (0.40) | LTB4R2PTPN11PTPRO | |
| SCHEMBL2861907 | 0.81 | PDE6D (0.48) | PTPN11PTPROHDAC3HDAC1HDAC2 | |
| SCHEMBL13711648 | 0.78 | LTB4R2 (0.76) | LTB4R2AGTR1 | |
| SCHEMBL1733837 | 0.78 | PTPN11 (0.60) | LTB4R2PTPN11PTPROAGTR1 | |
| SCHEMBL1733830 | 0.78 | PTPN11 (0.71) | LTB4R2PTPN11PTPROAGTR1 | |
| SCHEMBL13711777 | 0.77 | LTB4R2 (0.48) | LTB4R2 | |
| SCHEMBL2854924 | 0.77 | RARB (0.55) | LTB4R2PTPN11PTPROHDAC3HDAC1 | |
| SCHEMBL570747 | 0.76 | ESR1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | LTB4R2 827/4885PTPN11 97/4885PTPRO 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.